Research ExplorerPublicationsCancer-testis antigens are commonly expressed in multiple my...

Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.

Standard

Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. / Atanackovic, Djordje; Arfsten, Julia; Cao, Yanran; Gnjatic, Sacha; Schnieders, Frank; Bartels, Katrin; Schilling, Georgia; Faltz, Christiane; Wolschke, Christine; Dierlamm, Judith; Ritter, Gerd; Eiermann, Thomas; Hossfeld, Dieter Kurt; Zander, Axel R.; Jungbluth, Achim A; Old, Lloyd J; Bokemeyer, Carsten; Kröger, Nicolaus.

In: BLOOD, Vol. 109, No. 3, 3, 2007, p. 1103-1112.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Atanackovic, D, Arfsten, J, Cao, Y, Gnjatic, S, Schnieders, F, Bartels, K, Schilling, G, Faltz, C, Wolschke, C, Dierlamm, J, Ritter, G, Eiermann, T, Hossfeld, DK, Zander, AR, Jungbluth, AA, Old, LJ, Bokemeyer, C & Kröger, N 2007, 'Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.', BLOOD, vol. 109, no. 3, 3, pp. 1103-1112. <http://www.ncbi.nlm.nih.gov/pubmed/17023585?dopt=Citation>

APA

Atanackovic, D., Arfsten, J., Cao, Y., Gnjatic, S., Schnieders, F., Bartels, K., Schilling, G., Faltz, C., Wolschke, C., Dierlamm, J., Ritter, G., Eiermann, T., Hossfeld, D. K., Zander, A. R., Jungbluth, A. A., Old, L. J., Bokemeyer, C., & Kröger, N. (2007). Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. BLOOD, 109(3), 1103-1112. [3]. http://www.ncbi.nlm.nih.gov/pubmed/17023585?dopt=Citation

Vancouver

Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. BLOOD. 2007;109(3):1103-1112. 3.

Bibtex

@article{ca533001c4d041eb8308156d86906789,
title = "Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.",
abstract = "Immunotherapies using cancer-testis (CT) antigens as targets represent a potentially useful treatment in patients with multiple myeloma (MM) who commonly show recurrent disease following chemotherapy. We analyzed the expression of 11 CT antigens in bone marrow samples from patients with MM (n=55) and healthy donors (n=32) using reverse transcriptase-polymerase chain reaction (RT-PCR). CT antigens were frequently expressed in MM with 56% (MAGEC2), 55% (MAGEA3), 35% (SSX1), 20% (SSX4, SSX5), 16% (SSX2), 15% (BAGE), 7% (NY-ESO-1), and 6% (ADAM2, LIPI) expressing the given antigen. Importantly, CT antigens were not expressed in healthy bone marrow. Analyzing patients with MM (n=66) for antibody responses against MAGEA3, SSX2, and NY-ESO-1, we found strong antibody responses against CT antigens preferentially in patients who had received allogeneic stem cell transplantation (alloSCT). Antibody responses against NY-ESO-1 correlated with NY-ESO-1-specific CD4+ and CD8+ T-cell responses against peptide NY-ESO-1(51-62) and CD4+ responses against NY-ESO-1(121-140) in 1 of these patients. These allogeneic immune responses were not detectable in pretransplantation samples and in the patients' stem cell donors, indicating that CT antigens might indeed represent natural targets for graft-versus-myeloma effects. Immune responses induced by alloSCT could be boosted by active CT antigen-specific immunotherapy, which might help to achieve long-lasting remissions in patients with MM.",
author = "Djordje Atanackovic and Julia Arfsten and Yanran Cao and Sacha Gnjatic and Frank Schnieders and Katrin Bartels and Georgia Schilling and Christiane Faltz and Christine Wolschke and Judith Dierlamm and Gerd Ritter and Thomas Eiermann and Hossfeld, {Dieter Kurt} and Zander, {Axel R.} and Jungbluth, {Achim A} and Old, {Lloyd J} and Carsten Bokemeyer and Nicolaus Kr{\"o}ger",
year = "2007",
language = "Deutsch",
volume = "109",
pages = "1103--1112",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

RIS

TY - JOUR

T1 - Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.

AU - Atanackovic, Djordje

AU - Arfsten, Julia

AU - Cao, Yanran

AU - Gnjatic, Sacha

AU - Schnieders, Frank

AU - Bartels, Katrin

AU - Schilling, Georgia

AU - Faltz, Christiane

AU - Wolschke, Christine

AU - Dierlamm, Judith

AU - Ritter, Gerd

AU - Eiermann, Thomas

AU - Hossfeld, Dieter Kurt

AU - Zander, Axel R.

AU - Jungbluth, Achim A

AU - Old, Lloyd J

AU - Bokemeyer, Carsten

AU - Kröger, Nicolaus

PY - 2007

Y1 - 2007

N2 - Immunotherapies using cancer-testis (CT) antigens as targets represent a potentially useful treatment in patients with multiple myeloma (MM) who commonly show recurrent disease following chemotherapy. We analyzed the expression of 11 CT antigens in bone marrow samples from patients with MM (n=55) and healthy donors (n=32) using reverse transcriptase-polymerase chain reaction (RT-PCR). CT antigens were frequently expressed in MM with 56% (MAGEC2), 55% (MAGEA3), 35% (SSX1), 20% (SSX4, SSX5), 16% (SSX2), 15% (BAGE), 7% (NY-ESO-1), and 6% (ADAM2, LIPI) expressing the given antigen. Importantly, CT antigens were not expressed in healthy bone marrow. Analyzing patients with MM (n=66) for antibody responses against MAGEA3, SSX2, and NY-ESO-1, we found strong antibody responses against CT antigens preferentially in patients who had received allogeneic stem cell transplantation (alloSCT). Antibody responses against NY-ESO-1 correlated with NY-ESO-1-specific CD4+ and CD8+ T-cell responses against peptide NY-ESO-1(51-62) and CD4+ responses against NY-ESO-1(121-140) in 1 of these patients. These allogeneic immune responses were not detectable in pretransplantation samples and in the patients' stem cell donors, indicating that CT antigens might indeed represent natural targets for graft-versus-myeloma effects. Immune responses induced by alloSCT could be boosted by active CT antigen-specific immunotherapy, which might help to achieve long-lasting remissions in patients with MM.

AB - Immunotherapies using cancer-testis (CT) antigens as targets represent a potentially useful treatment in patients with multiple myeloma (MM) who commonly show recurrent disease following chemotherapy. We analyzed the expression of 11 CT antigens in bone marrow samples from patients with MM (n=55) and healthy donors (n=32) using reverse transcriptase-polymerase chain reaction (RT-PCR). CT antigens were frequently expressed in MM with 56% (MAGEC2), 55% (MAGEA3), 35% (SSX1), 20% (SSX4, SSX5), 16% (SSX2), 15% (BAGE), 7% (NY-ESO-1), and 6% (ADAM2, LIPI) expressing the given antigen. Importantly, CT antigens were not expressed in healthy bone marrow. Analyzing patients with MM (n=66) for antibody responses against MAGEA3, SSX2, and NY-ESO-1, we found strong antibody responses against CT antigens preferentially in patients who had received allogeneic stem cell transplantation (alloSCT). Antibody responses against NY-ESO-1 correlated with NY-ESO-1-specific CD4+ and CD8+ T-cell responses against peptide NY-ESO-1(51-62) and CD4+ responses against NY-ESO-1(121-140) in 1 of these patients. These allogeneic immune responses were not detectable in pretransplantation samples and in the patients' stem cell donors, indicating that CT antigens might indeed represent natural targets for graft-versus-myeloma effects. Immune responses induced by alloSCT could be boosted by active CT antigen-specific immunotherapy, which might help to achieve long-lasting remissions in patients with MM.

M3 - SCORING: Zeitschriftenaufsatz

VL - 109

SP - 1103

EP - 1112

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 3

M1 - 3

ER -